trabajo informatica 2011

1. Diana Vanessa GonzalezRodriguez Enfermedad de Hansen

2. La Lepra es una enfermedad infecciosa crónica, se trasmite de persona a persona es de baja contagiosidad afecta a personas de cualquier edad y genero, producida por el Mycobacteriumleprae, que afecta el sistema nervioso periférico, la piel, la nariz, los ojos, el tracto respiratorio superior, las manos, los pies, el músculo estriado, algunos huesos pequeños, los testículos y el riñón

3. ABSTRACT An Indian patient of histoid leprosy presenting de novo, having numerous solid staining bacilli inside the intact epidermis and eliminating bacilli from the intact and the eroded epidermis, is reported. The diagnosis, suggested by the clinical features, was confirmed histopathologically. This unusual report indicates possible participation of skin in leprosy transmission. 1 . Transepidermal elimination of Mycobacterium leprae in histoid leprosy: A case report suggesting possible participation of skin in leprosy transmission

4. 1. Sehgal VN, Aggarwal A, Srivastava G, Sharma N, Sharma S. Evolution of histoidleprosy (de novo) in lepromatous (multibacillary) leprosy. Int J Dermatol 2005;44:576-8 2. Satapathy J, Kar BR, Job CK. Presence of Mycobacteriumleprae in theepidermalcells of lepromatousskin and itssignificance. Indian J DermatolVenereolLeprol 2005;71:267-9. 3. Seo VH, Cho W, Choi HY, Hah YM, Cho SN. Mycobacterium leprae in the epidermis: Ultrastructuralstudy I. Int J LeprOther MycobactDis 1995;63:101-4. 4. Okada S, Komura J, Nishiura M. Mycobacteriumlepraefound in epidermalcellsby electro

5. Nombre del articulo: Transepidermal elimination of Mycobacterium leprae in histoid leprosy: A case report suggesting possible participation of skin in leprosy transmissio Autor: Department of Dermatology, Venereology and Leprosy, J.L.N Hospital & Research Center, Bhilai Steel Plant, Bhilai, India Link: http://biblioteca.fucsalud.edu.co:2093/pdf25_26/pdf/2011/SV4/01Jan11/57457412.pdf?T=P&P=AN&K=57457412&S=R&D=byh&EbscoContent=dGJyMNXb4kSep7Q4xNvgOLCmr0mep7JSs6a4TbGWxWXS&ContentCustomer=dGJyMPGrt0m3qa9QuePfgeyx44Dt6fIA Bases de datos: http://biblioteca.fucsalud.edu.co:2079/ehost/results?hid=110&sid=7157a3f2-08f9-4aed-b9b6-7368555ed6fb%40sessionmgr113&vid=9&bquery=(leprosy)&bdata=JmRiPWJ5aCZsYW5nPWVzJnR5cGU9MCZzaXRlPWVob3N0LWxpdmU%3d / EBSCOHOST

6. ABSTRACT Leprosy was supposed to be eliminated by WHO at the global level by the end of the year 2000; however, it still remains a significant public health problem at a national level in six countries, where India alone accounts for 64% of prevalence and 78% of new case detection, worldwide. The global registered prevalence of leprosy at the beginning of 2006 was 219 826 cases. The number of new cases reported during 2005 was 296 499. The clinical diagnosis of leprosy continues to be based on patients having one or more of the three cardinal signs: hypopigmented or reddish anesthetic skin lesion(s); involvement of the peripheral nerves, as demonstrated by definite thickening with loss of sensation in the area of distribution; and a positive skin smear for acid-fast bacilli. Multidrug therapy (MDT) for leprosy has proved to be highly effective, with low relapse rates resulting in a dramatic decrease in the global prevalence rate to less than one case per 10 000 by the end of the year 2000. It was thought to be worthwhile to review the progress made in the treatment of this neglected tropical disease from the time diaminodiphenylsulfone (dapsone) monotherapy was introduced in its management, to the rapidly changing situation following the advent of WHO-recommended MDT and subsequently to short-course newer drug regimens with the prime objective to eliminate/eradicate leprosy from the world. Several permutations and combinations of drugs were utilized, the outline of which are succinctly depicted in the following account. Furthermore, a synopsis of the role of immunoprophylaxis therapy has briefly been reviewed to arrive at the possible current status. It is expected that this article is not only essential at this point in time but is also likely to make clear the intricacies surrounding its management. 2. The imperatives of leprosy treatment in the pre- and post-global leprosy elimination era: Appraisal of changing the scenario to current status.

7. Journal of Dermatological Treatment, Apr2008, Vol. 19 Issue 2, p82-91, 10p, 8 Charts Chart; found on p83 Journal of Dermatological Treatment, Apr2008, Vol. 19 Issue 2, p82-91, 10p, 8 Charts Chart; found on p84

8. Nombre articulo: The imperatives of leprosy treatment in the pre- and post-global leprosy elimination era: Appraisal of changing the scenario to current status. Autor: - Sehgal, VirendraDermato-Venereology (Skin/VD) Centre, SehgalNursing Home, Delhi,India drsehgal@ndf.vsnl.net.in- Sardana, KabirDepartment of Dermatology and STD, Maulanda Azad Medical College, New Delhi, India- Dogra, SunilDepartment of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India Link: http://biblioteca.fucsalud.edu.co:2079/ehost/detail?hid=110&sid=7157a3f2-08f9-4aed-b9b6-7368555ed6fb%40sessionmgr113&vid=12&bdata=Jmxhbmc9ZXMmc2l0ZT1laG9zdC1saXZl#db=byh&AN=32069367 Bases de datos: BiomedicalReferenceCollection: Comprehensive

9. ABSTRACT Granulomatousmycosisfungoides (GMF) is a raretype of cutaneous T celllymphoma. A 38-year-old marriedmalepresentedwithdecreasedsweatingalloverthebodyforlast 8 years, progressiveredness and scalingoverbodyfor 2 years and multiplenoduloulcerativelesionsoverthebodyfor 1 year. Cutaneousexaminationrevealedgeneralizederythema and scalingwithpoikilodermatouschangesoverchest and upper back alongwithmultiplenoduloulcerativelesions. Skinbiopsyfrom a nodular lesionrevealed dense granulomatousinfiltrate of atypicallymphocyteswithepidermotropism and sparing of appendages. Diagnosis of GMF wasmade. Computedtomographicscan of thorax, abdomen and pelvis revealedaxillary and inguinal lymphadenopathy.Immunohistochemistryrevealedleukocytecommonantigen and CD3 positivitysuggestive of T cellorigin. Patientwasstartedon CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin and Prednisolone) regimen of chemotherapywithmarkedimprovementafterthreecycles of chemotherapy. This case hadsomeclinicalresemblancetolepromatous leprosy. 3. Granulomatousmycosisfungoideswithhypohidrosismimickinglepromatous leprosy

10. IndianJournal of Dermatology, Venereology & Leprology, Nov/Dec2010, Vol. 76 Issue 6, p686-690, 5p, 6 Color Photographs, 1 ChartColor Photograph; foundon p688

11. IndianJournal of Dermatology, Venereology & Leprology, Nov/Dec2010, Vol. 76 Issue 6, p686-690, 5p, 6 Color Photographs, 1 ChartColor Photograph; foundon p688

12. IndianJournal of Dermatology, Venereology & Leprology, Nov/Dec2010, Vol. 76 Issue 6, p686-690, 5p, 6 Color Photographs, 1 Chart Color Photograph; foundon p688

13. Nombre del articulo: Granulomatousmycosisfungoideswithhypohidrosismimickinglepromatous leprosy Autor:MedknowPublications & Media Pvt. Ltd. B-9, Kanara Business Centre Off Link Rd, GhatkoparMumbai 400075 India Link: http://biblioteca.fucsalud.edu.co:2079/ehost/detail?hid=110&sid=7157a3f2-08f9-4aed-b9b6-7368555ed6fb%40sessionmgr113&vid=14&bdata=Jmxhbmc9ZXMmc2l0ZT1laG9zdC1saXZl#db=byh&AN=55412551 Bases de datos: BiomedicalReferenceCollection: Comprehensive / EBSCOHOST

14. ABSTRACT A fresh focus on histoid leprosy is the primary objective of this article, especially in the context of the postglobal leprosy elimination era. The emergence of the entity following dapsonemonotherapy is well recognized, in addition to de novo cases. Irregular and inadequate therapies, coupled with resistance to dapsone and/or mutant organisms, are responsible. It was considered to be worthwhile to take stock of the condition through its history, nomenclature, epidemiology, clinical characteristics, diagnosis, and differential diagnosis. The bacteriologic and histopathologic features and immunologic profile are also described. 4. Histoid leprosy: the impact of the entity on the postglobal leprosy elimination era.

15. International Journal of Dermatology, Jun2009, Vol. 48 Issue 6, p603-610, 8p, 5 Color Photographs, 1 ChartColor Photograph; found on p605 International Journal of Dermatology, Jun2009, Vol. 48 Issue 6, p603-610, 8p, 5 Color Photographs, 1 ChartColor Photograph; found on p605

16. Nombre articulo: Histoid leprosy: the impact of the entity on the postglobal leprosy elimination era. Autor:Sehgal, Virendra Dermato-Venereology (Skin/VD) Centre, SehgalNursing Home, A-6 Panchwati, Delhi 110 033, India drsehgal@ndf.vsnl.net.inSrivastava, GovindSingh, NavjeevanPrasad, Pullabatla V. S. Link: http://biblioteca.fucsalud.edu.co:2079/ehost/detail?hid=110&sid=7157a3f2-08f9-4aed-b9b6-7368555ed6fb%40sessionmgr113&vid=14&bdata=Jmxhbmc9ZXMmc2l0ZT1laG9zdC1saXZl#db=byh&AN=40414008 Bases de datos: BiomedicalReferenceCollection: Comprehensive

17. Thalidomide never disappeared. Since the discovery in the 1960s of its ability to cause birth defects, the drug has continued to be studied throughout the world to treat cancer and other life-threatening or disabling conditions. FDA approved the drug for the first time in this country in 1998 under the brand name Thalomid, manufactured by Celgene Corporation of Warren, N.J. It was approved for one condition only: erythemanodosumleprosum (ENL), a severe and debilitating complication of leprosy (Hansen's disease). Because of the dangers the drug still presents to the unborn, FDA took unprecedented regulatory steps to control Thalomid's marketing. Extensive patient education about risks, a patient registry of those taking the drug, and mandatory pregnancy testing at least monthly for sexually active women of childbearing age are all part of the program to prevent another thalidomide tragedy. Thalidomide continues to be evaluated in similarly controlled FDA-approved studies. The drug inhibits the growth of new blood vessels in tumors, and has shown the most promise in treating multiple myeloma (a cancer of the bone marrow) and Kaposi's sarcoma (an AIDS-related cancer), says William Figg, PharmD, a senior investigator at the National Cancer Institute. Thalidomide has also shown potential to treat solid tumors in the prostate and brain, as well as graft-versus-host disease, a complication of bone marrow transplants. Kelsey served on FDA's working group, formed in 1994, to develop and implement uniform standards of safety for clinical studies using thalidomide. "She provided this moral and scientific backbone to the group, given her previous experience with the drug," says Debra Birnkrant, MD, the working group's chairperson. Kelsey knows that thalidomide can give relief to patients with leprosy and perhaps other diseases, but is concerned about its widespread use--particularly with the availability of Internet sales. "We need to take precautions," she says, "because people forget very soon." 5. THALIDOMIDE TODAY

18. Nombre articulo: THALIDOMIDE TODAY Articulo: De: Bren, Linda, FDA Consumer, 03621332, Mar/Apr2001, Vol. 35, Fascículo 2 Link: http://biblioteca.fucsalud.edu.co:2079/ehost/detail?hid=110&sid=7157a3f2-08f9-4aed-b9b6-7368555ed6fb%40sessionmgr113&vid=12&bdata=Jmxhbmc9ZXMmc2l0ZT1laG9zdC1saXZl#db=awh&AN=4219045 Bases de datos: AltHealthWatch

19. Abstract Leprosy is an infectious contagious disease known since Biblical times. Global effort for disease control reveals intricate convergences of national history and of medical, governmental, and international policies. The study describes the history of Hansen's disease and control actions undertaken in the state of São Paulo starting in the 19th century and its connection with the development of public health in that state, by means of a bibliographic and documental analysis. 6. Hansen's disease control in the State of São Paulo: a historical analysis

20. Nombre articulo: Hansen's disease control in the State of São Paulo: a historical analysis Autores: Opromolla PA, Laurenti R. Estado da Saúde de São Paulo, São Paulo, Brasil opromolla@saude.sp.gov.br Link: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0034-89102011000100022&lng=en&nrm=iso&tlng=en Bases de datos: Pubmed. gov

21. A lepromatous patient treated with dapsone in the pre-MDT era to the point of smear negativity (> 6 years), relapsed 5 years after stopping treatment. He was then put on WHO-MDT for multibacillary (MB) leprosy, and was treated again; he had negative slit skin smears (3 years). He again presented with a relapse of leprosy 17 years after stopping treatment, and this time he presented with borderline leprosy in reaction. 7. Two microbiological relapses in a patient with lepromatous leprosy

22. Leprosy Review, Sep2008, Vol. 79 Issue 3, p331-334, 4p, 2 Black and White PhotographsBlack and White Photograph; found on p332

23. Leprosy Review, Sep2008, Vol. 79 Issue 3, p331-334, 4p, 2 Black and White PhotographsBlack and White Photograph; found on p333

24. Nombre articulo: Two microbiological relapses in a patient with lepromatous leprosy Autor: Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK NationalJALMA Institutefor Leprosy and OtherMycobacterialDiseases, ICMR, Tajganj, Agra 282 001, India Link: http://biblioteca.fucsalud.edu.co:2079/ehost/detail?hid=110&sid=7157a3f2-08f9-4aed-b9b6-7368555ed6fb%40sessionmgr113&vid=16&bdata=Jmxhbmc9ZXMmc2l0ZT1laG9zdC1saXZl#db=mnh&AN=19009984 Base de datos: MEDLINE with Full Text